ATE340794T1 - Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes - Google Patents
Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetesInfo
- Publication number
- ATE340794T1 ATE340794T1 AT02752178T AT02752178T ATE340794T1 AT E340794 T1 ATE340794 T1 AT E340794T1 AT 02752178 T AT02752178 T AT 02752178T AT 02752178 T AT02752178 T AT 02752178T AT E340794 T1 ATE340794 T1 AT E340794T1
- Authority
- AT
- Austria
- Prior art keywords
- diabetes
- beta
- treatment
- type
- indole derivatives
- Prior art date
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 239000000048 adrenergic agonist Substances 0.000 title 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 title 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000004130 lipolysis Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940126158 β3 adrenergic receptor agonist Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31227501P | 2001-08-14 | 2001-08-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE340794T1 true ATE340794T1 (de) | 2006-10-15 |
Family
ID=23210688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02752178T ATE340794T1 (de) | 2001-08-14 | 2002-08-06 | Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7208505B2 (de) |
| EP (1) | EP1421078B1 (de) |
| JP (1) | JP2005501856A (de) |
| AT (1) | ATE340794T1 (de) |
| DE (1) | DE60215028T2 (de) |
| ES (1) | ES2272749T3 (de) |
| WO (1) | WO2003016307A1 (de) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003016307A1 (en) | 2001-08-14 | 2003-02-27 | Eli Lilly And Company | β3 ADRENERGIC AGONISTS |
| ATE297925T1 (de) * | 2001-11-20 | 2005-07-15 | Lilly Co Eli | 3-substituierte oxindol beta 3 agonisten |
| AU2002353844A1 (en) * | 2001-11-20 | 2003-06-10 | Eli Lilly And Company | Beta 3 adrenergic agonists |
| WO2003059348A1 (en) | 2002-01-11 | 2003-07-24 | Eli Lilly And Company | 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7435837B2 (en) | 2003-10-24 | 2008-10-14 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
| EP1734963A4 (de) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | Verfahren zur behandlung von menschen mit metabolischen und anthropometrischen störungen |
| US7622491B2 (en) * | 2004-08-13 | 2009-11-24 | Metabolex Inc. | Modulators of PPAR and methods of their preparation |
| DE102005052127A1 (de) * | 2005-10-28 | 2007-05-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue indol-haltige Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| EP1957483A1 (de) | 2005-12-01 | 2008-08-20 | F.Hoffmann-La Roche Ag | Neue vinyloge säurederivate |
| EP2032532B8 (de) | 2006-06-12 | 2015-07-01 | Novartis AG | Verfahren zur Herstellung von Salzen des N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamids |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| CA2726917C (en) | 2008-06-04 | 2018-06-26 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP2321341B1 (de) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase |
| US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| CA2826649C (en) | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| RU2015106909A (ru) | 2012-08-02 | 2016-09-27 | Мерк Шарп И Доум Корп. | Антидиабетические трициклические соединения |
| BR112015019836A2 (pt) | 2013-02-22 | 2017-07-18 | Merck Sharp & Dohme | composto, composição farmacêutica, e, uso de um composto |
| EP2970119B1 (de) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Neuartige indolderivate als antidiabetika |
| WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
| CN105764916B (zh) | 2013-06-05 | 2021-05-18 | 博士医疗爱尔兰有限公司 | 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法 |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH624395A5 (de) | 1976-01-08 | 1981-07-31 | Ciba Geigy Ag | |
| US4314943A (en) | 1977-07-13 | 1982-02-09 | Mead Johnson & Company | Heterocyclic substituted aryloxy 3-indolyl-tertiary butylaminopropanols |
| US4234595A (en) | 1977-07-13 | 1980-11-18 | Mead Johnson & Company | 3-Indolyl-tertiary butylaminopropanols |
| CA1116598A (en) | 1977-07-13 | 1982-01-19 | William T. Comer | 3-indolyl-tertiary butylaminopropanols |
| JPS6010021B2 (ja) | 1979-01-31 | 1985-03-14 | 田辺製薬株式会社 | 新規ベンジルアルコ−ル誘導体及びその製法 |
| DE3423429A1 (de) * | 1984-06-26 | 1986-01-02 | Beiersdorf Ag, 2000 Hamburg | Substituierte phenoxyalkylaminopropanole, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen |
| DE3426419A1 (de) | 1984-07-18 | 1986-01-23 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte |
| US4728651A (en) | 1985-10-24 | 1988-03-01 | Hoechst-Roussel Pharmaceuticals Inc. | Antihypertensive thieno-isoxazoles and -pyrazoles |
| GB8528633D0 (en) | 1985-11-21 | 1985-12-24 | Beecham Group Plc | Compounds |
| US5451677A (en) | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| CA2145257A1 (en) | 1994-03-23 | 1995-09-24 | Takashi Fujita | Thiazolidine and oxazolidine derivatives, their preparation and their medical use |
| IL113410A (en) | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
| US5705515A (en) | 1994-04-26 | 1998-01-06 | Merck & Co., Inc. | Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity |
| ZA967892B (en) | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
| WO1997046556A1 (en) | 1996-06-07 | 1997-12-11 | Merck & Co., Inc. | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
| US5808080A (en) | 1996-09-05 | 1998-09-15 | Eli Lilly And Company | Selective β3 adrenergic agonists |
| ATE215369T1 (de) | 1996-09-05 | 2002-04-15 | Lilly Co Eli | Carbazolanaloge als selektive beta3-adrenergische agonisten |
| US6011048A (en) | 1997-01-28 | 2000-01-04 | Merck & Co., Inc. | Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity |
| EP0968209A1 (de) | 1997-01-28 | 2000-01-05 | Merck & Co., Inc. | Thiazole benzenesulfonamide als beta3-agonisten zur behandlung von diabetes und fettleibigkeit |
| AUPP796798A0 (en) | 1998-12-30 | 1999-01-28 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| JP2003055344A (ja) | 1999-01-29 | 2003-02-26 | Dainippon Pharmaceut Co Ltd | ３，７−ジ置換インドール誘導体及びそれを含有する医薬組成物 |
| AU6050000A (en) | 1999-07-22 | 2001-02-13 | Eli Lilly And Company | Improved method of treating type ii diabetes and obesity |
| WO2001035947A2 (en) | 1999-11-15 | 2001-05-25 | Eli Lilly And Company | Treating wasting syndromes with aryloxy propanolamines |
| WO2001036412A1 (en) | 1999-11-15 | 2001-05-25 | Eli Lilly And Company | Process for the preparation of aryloxy propanolamines |
| AU2001236471A1 (en) | 2000-01-18 | 2001-07-31 | Neurogen Corporation | Imidazopyridines and related azacyclic derivatives as selective modulators of bradykinin b2 receptors |
| GB0015727D0 (en) | 2000-06-27 | 2000-08-16 | Pfizer Ltd | Purine derivatives |
| IL152528A0 (en) * | 2000-07-13 | 2003-05-29 | Lilly Co Eli | Beta3 adrenergic agonists |
| IL154928A0 (en) | 2000-11-10 | 2003-10-31 | Lilly Co Eli | 3-substituted oxindole beta 3 agonists |
| EP1444224B1 (de) | 2001-08-14 | 2006-05-03 | Eli Lilly And Company | 3-substituierte oxindol-beta-3-agonisten |
| WO2003016307A1 (en) | 2001-08-14 | 2003-02-27 | Eli Lilly And Company | β3 ADRENERGIC AGONISTS |
| AU2002353844A1 (en) | 2001-11-20 | 2003-06-10 | Eli Lilly And Company | Beta 3 adrenergic agonists |
| ATE297925T1 (de) | 2001-11-20 | 2005-07-15 | Lilly Co Eli | 3-substituierte oxindol beta 3 agonisten |
-
2002
- 2002-08-06 WO PCT/US2002/021317 patent/WO2003016307A1/en not_active Ceased
- 2002-08-06 EP EP02752178A patent/EP1421078B1/de not_active Expired - Lifetime
- 2002-08-06 JP JP2003521230A patent/JP2005501856A/ja active Pending
- 2002-08-06 AT AT02752178T patent/ATE340794T1/de not_active IP Right Cessation
- 2002-08-06 DE DE60215028T patent/DE60215028T2/de not_active Expired - Fee Related
- 2002-08-06 ES ES02752178T patent/ES2272749T3/es not_active Expired - Lifetime
- 2002-08-06 US US10/486,867 patent/US7208505B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20050080110A1 (en) | 2005-04-14 |
| WO2003016307A1 (en) | 2003-02-27 |
| ES2272749T3 (es) | 2007-05-01 |
| JP2005501856A (ja) | 2005-01-20 |
| US7208505B2 (en) | 2007-04-24 |
| EP1421078B1 (de) | 2006-09-27 |
| DE60215028T2 (de) | 2007-03-15 |
| DE60215028D1 (de) | 2006-11-09 |
| EP1421078A1 (de) | 2004-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE340794T1 (de) | Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes | |
| ATE325119T1 (de) | 3-substituierte oxindol-beta-3-agonisten | |
| DE60120748D1 (de) | 3-substituierte oxindolderivate als beta-3-agonisten | |
| DE69400824D1 (de) | Indol-derivate als 5-ht1-ähnliche antagonisten zur behandlung von migräne | |
| DE602004012858D1 (de) | 2-aminobenzothiazole als cb1 rezeptor inverse agonisten | |
| EA200700047A1 (ru) | Новые алкильные производные в качестве метаботропных рецепторов глутамата | |
| BRPI0418149A (pt) | derivados heterocìclicos como agonistas do receptor de gprc | |
| NO20082136L (no) | 1,5-substituerte indol-2-yl-amidderivater | |
| ATE361922T1 (de) | Pyrrol-substituierte indole als inhibitoren von pai-1 | |
| EA200600049A1 (ru) | Способы получения 3 - бензазепинов | |
| NO20055516L (no) | Kannabinoidreceptorligander og anvendelser derav | |
| EA200700352A1 (ru) | Энантиомерно чистые аминогетероарильные соединения в качестве ингибиторов протеинкиназы | |
| EA200500091A1 (ru) | Фосфатные соли карведилола и/или их сольваты, соответствующие композиции и/или способы лечения | |
| MXPA03000308A (es) | Agonistas beta3 adrenergicos. | |
| NO20076638L (no) | Nye 8-sulfonylamino-3-aminosubstituerte kroman- eller tetrahydronaftalenderivater som modulerer 5HT6-reseptoren | |
| MXPA05007115A (es) | Nuevos agonistas inversos del receptor cb 1. | |
| ATE540044T1 (de) | Lpa-rezeptor-agonisten und antagonisten und verwendungsverfahren dafür | |
| SG164283A1 (en) | New benzimidazole derivatives | |
| ATE364044T1 (de) | 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit | |
| PE20091649A1 (es) | Derivados de pirrolidinilo | |
| EA200702058A1 (ru) | Новые фармацевтические соединения | |
| BRPI0509186A (pt) | 1,3-diaminopropanos 2-amino-e 2-tio-substituìdos | |
| DE602006014305D1 (de) | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors | |
| ATE307133T1 (de) | Hexahydroazepino(4,5-g)indole und -indoline als 5-ht-rezeptor-liganden | |
| DE602006004964D1 (de) | Dihydrochinazolinone als 5ht-modulatoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |